Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05561751 | Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | PHASE2 | COMPLETED | 30 | — | — | Feb 13, 2023 | Oct 31, 2025 | Feb 12, 2026 | 10 | United States |
Determine the proportion of patients that will achieve \>=2 x 10\^6 CD34+ cells/kg in 2 leukapheresis sessions following treatment
| Arm | Type | Description |
|---|---|---|
| GPC-100 in combination with propranolol; | EXPERIMENTAL | Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or |
| GPC-100 in combination with propranolol and G-CSF | EXPERIMENTAL | Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF. |
| Name | Type | Description |
|---|---|---|
| GPC-100 | DRUG | GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min |
| Propranolol | DRUG | propranolol |
| G-CSF | DRUG | G-CSF |
Inclusion Criteria To be eligible to participate in this study, patients must meet all the following criteria: 1. Male or female, greater than or equal to18 years of age; 2. Patients with diagnosis of MM per the International Myeloma Working Group criteria ; 3. Eligible for ASCT at the Investigato...